Treprostinil Inhalation Powder

DRUG2 trials

Sponsors

Mannkind Corporation, United Therapeutics

Conditions

Pulmonary Arterial Hypertension

Phase 1

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

CompletedNCT03464864

Mannkind CorporationPulmonary Arterial Hypertension

Start: 2018-03-09End: 2018-06-05Updated: 2018-10-30

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

CompletedNCT03950739

United TherapeuticsPulmonary Arterial Hypertension

Start: 2019-09-17End: 2023-08-22Updated: 2024-11-01

Related Papers

BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

Respiratory Medicine2025-08-273 citations

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

Pulmonary Circulation2022-03-2331 citations